Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

INTRODUCTION: Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizk, Dana V., Rovin, Brad H., Zhang, Hong, Kashihara, Naoki, Maes, Bart, Trimarchi, Hernán, Perkovic, Vlado, Meier, Matthias, Kollins, Dmitrij, Papachristofi, Olympia, Charney, Alan, Barratt, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166738/
https://www.ncbi.nlm.nih.gov/pubmed/37180505
http://dx.doi.org/10.1016/j.ekir.2023.01.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166738/
https://www.ncbi.nlm.nih.gov/pubmed/37180505
http://dx.doi.org/10.1016/j.ekir.2023.01.041

Ejemplares similares